# Akari Therapeutics Plc: filings

AKTX · Nasdaq · CIK 1541157 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aktx.md) · [Financials](/companies/aktx/financials.md) · [Filings](/companies/aktx/filings.md) · [Insiders](/companies/aktx/insiders.md)

## Reports and events: 308 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (6-K 188, 4 97, 8-K 63, EFFECT 50, 3 33, POS AM 25, UPLOAD 25, CORRESP 23, 424B3 22, SC 13G/A 17, D 13, 10-Q 12, DEFA14A 11, 424B5 10, 20-F 9, F-1 9, F-1/A 9, SC 13D/A 9, SC 13G 9, DEF 14A 8, S-8 7, 425 6, F-3 6, 10-K 5, S-1 5, S-3 5, 20FR12G/A 4, NT 10-Q 4, PRE 14A 4, ARS 3, F-3/A 3, F-6 POS 3, RW 3, SC 13D 3, SCHEDULE 13D/A 3, SCHEDULE 13G 3, 20-F/A 2, 20FR12G 2, 8-K/A 2, F-6EF 2, NT 20-F 2, S-3/A 2, S-4/A 2, 424B2 1, 424B4 1, 4/A 1, 6-K/A 1, 8-A12B 1, CERTNAS 1, D/A 1, DEFM14A 1, DRS 1, F-6 1, F-6/A 1, NT 10-K 1, PREM14A 1, S-1/A 1, S-4 1, SCHEDULE 13G/A 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-30 | 16:45 ET | [8-K](/filings/0001493152-26-049446.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-049446 |
| 2026-10-01 | 17:00 ET | [DEF 14A](/filings/0001493152-26-045371.md) | Proxy statement, period 2026-10-01 | 0001493152-26-045371 |
| 2026-10-01 | 16:45 ET | [8-K](/filings/0001493152-26-045364.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-045364 |
| 2026-08-13 | 16:02 ET | [8-K](/filings/0001493152-26-037736.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-037736 |
| 2026-08-13 | 16:00 ET | [10-Q](/filings/0001493152-26-037730.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037730 |
| 2026-07-02 | 17:25 ET | [8-K](/filings/0001493152-26-031972.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-031972 |
| 2026-06-26 | 17:15 ET | [8-K](/filings/0001493152-26-030341.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-030341 |
| 2026-06-26 | 17:00 ET | [S-1/A](/filings/0001493152-26-030330.md) | Registration statement, amended | 0001493152-26-030330 |
| 2026-06-04 | 16:30 ET | [DEF 14A](/filings/0001493152-26-027279.md) | Proxy statement, period 2026-06-04 | 0001493152-26-027279 |
| 2026-05-22 | 16:30 ET | [8-K](/filings/0001493152-26-025037.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-025037 |
| 2026-05-19 | 17:00 ET | [10-Q](/filings/0001493152-26-024446.md) | Quarterly report, period 2026-03-31 | 0001493152-26-024446 |
| 2026-05-08 | 17:08 ET | [S-1](/filings/0001493152-26-022019.md) | Registration statement | 0001493152-26-022019 |
| 2026-03-30 | 17:39 ET | [10-K](/filings/0001493152-26-013664.md) | Annual report, period 2025-12-31 | 0001493152-26-013664 |
| 2026-03-17 | 17:07 ET | [8-K](/filings/0001493152-26-010602.md) | 3.03 Change to security holders’ rights; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-010602 |
| 2026-03-04 | 16:52 ET | [SCHEDULE 13D/A](/filings/0001493152-26-008880.md) | Ownership report, active investor, amended | 0001493152-26-008880 |
| 2026-03-04 | 16:44 ET | [SCHEDULE 13D/A](/filings/0001493152-26-008874.md) | Ownership report, active investor, amended | 0001493152-26-008874 |
| 2026-03-02 | 17:00 ET | [8-K](/filings/0001493152-26-008570.md) | 5.07 Shareholder vote results | 0001493152-26-008570 |
| 2026-02-02 | 11:15 ET | [DEF 14A](/filings/0001493152-26-004754.md) | Proxy statement, period 2026-02-02 | 0001493152-26-004754 |
| 2026-01-23 | 17:17 ET | [S-1](/filings/0001493152-26-003458.md) | Registration statement | 0001493152-26-003458 |
| 2025-12-17 | 10:15 ET | [8-K](/filings/0001493152-25-028075.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-25-028075 |
| 2025-12-16 | 16:30 ET | [8-K](/filings/0001493152-25-027969.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-25-027969 |
| 2025-12-08 | 08:00 ET | [8-K](/filings/0001493152-25-026533.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-25-026533 |
| 2025-11-26 | 17:00 ET | [8-K](/filings/0001493152-25-025177.md) | 3.01 Delisting notice | 0001493152-25-025177 |
| 2025-11-17 | 17:00 ET | [DEF 14A](/filings/0001493152-25-023911.md) | Proxy statement, period 2025-11-17 | 0001493152-25-023911 |
| 2025-11-17 | 16:56 ET | [S-1](/filings/0001493152-25-023908.md) | Registration statement | 0001493152-25-023908 |
| 2025-11-13 | 17:01 ET | [10-Q](/filings/0001493152-25-022390.md) | Quarterly report, period 2025-09-30 | 0001493152-25-022390 |
| 2025-10-23 | 16:45 ET | [8-K](/filings/0001493152-25-019112.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-25-019112 |
| 2025-10-16 | 09:20 ET | [8-K](/filings/0001493152-25-018269.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-25-018269 |
| 2025-10-15 | 08:45 ET | [8-K](/filings/0001493152-25-018091.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-25-018091 |
| 2025-09-29 | 17:00 ET | [8-K](/filings/0001493152-25-016039.md) | 8.01 Other events | 0001493152-25-016039 |
| 2025-09-25 | 17:00 ET | [8-K](/filings/0001493152-25-014962.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-25-014962 |
| 2025-08-29 | 17:15 ET | [S-1](/filings/0001641172-25-026052.md) | Registration statement | 0001641172-25-026052 |
| 2025-08-29 | 17:01 ET | [8-K](/filings/0001641172-25-026032.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001641172-25-026032 |
| 2025-08-21 | 17:00 ET | [8-K](/filings/0001641172-25-025104.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001641172-25-025104 |
| 2025-08-19 | 08:00 ET | [8-K](/filings/0001641172-25-024732.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001641172-25-024732 |
| 2025-08-13 | 17:01 ET | [10-Q](/filings/0001641172-25-023569.md) | Quarterly report, period 2025-06-30 | 0001641172-25-023569 |
| 2025-07-01 | 17:30 ET | [8-K](/filings/0000950170-25-092350.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-25-092350 |
| 2025-06-06 | 16:05 ET | [DEF 14A](/filings/0001641172-25-014023.md) | Proxy statement, period 2025-06-06 | 0001641172-25-014023 |
| 2025-05-15 | 08:58 ET | [8-K](/filings/0000950170-25-072046.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-072046 |
| 2025-05-14 | 16:51 ET | [10-Q](/filings/0000950170-25-071563.md) | Quarterly report, period 2025-03-31 | 0000950170-25-071563 |
| 2025-04-16 | 08:00 ET | [8-K](/filings/0000950170-25-054484.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-054484 |
| 2025-04-15 | 16:33 ET | [10-K](/filings/0000950170-25-054278.md) | Annual report, period 2024-12-31 | 0000950170-25-054278 |
| 2025-03-20 | 08:50 ET | [8-K](/filings/0000950170-25-042342.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-25-042342 |
| 2025-03-03 | 09:10 ET | [8-K](/filings/0001193125-25-043544.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-25-043544 |
| 2025-02-14 | 17:00 ET | [SCHEDULE 13D/A](/filings/0000950170-25-021393.md) | Ownership report, active investor, amended | 0000950170-25-021393 |
| 2025-01-13 | 08:00 ET | [8-K](/filings/0000950170-25-004576.md) | 7.01 Regulation FD disclosure | 0000950170-25-004576 |
| 2024-12-18 | 16:30 ET | [8-K](/filings/0000950170-24-137922.md) | 5.02 Departure or appointment of officers or directors | 0000950170-24-137922 |
| 2024-12-16 | 16:30 ET | [8-K](/filings/0000950170-24-136674.md) | 5.02 Departure or appointment of officers or directors | 0000950170-24-136674 |
| 2024-12-12 | 16:30 ET | [8-K](/filings/0000950170-24-135822.md) | 5.02 Departure or appointment of officers or directors | 0000950170-24-135822 |
| 2024-12-06 | 16:00 ET | [SC 13D/A](/filings/0001213900-24-106465.md) | Ownership report, active investor, amended | 0001213900-24-106465 |

Page 1 of 7. [Older](/companies/aktx/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 17:09 ET. No prices; not investment advice.